News

Aucta Pharmaceuticals, Inc. (Aucta), a technology based company focusing on the development and commercialization of Branded Specialty Products, announced that the Company has entered…
Read More...

BioCardia, Inc. announced it has signed an extension to a 2017 development agreement with AstraZeneca for BioCardia’s Helix biotherapeutic delivery catheter system. Under the terms…
Read More...

Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, and the Coalition for Epidemic Preparedness Innovations (CEPI)…
Read More...

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of dyslipidemia as well as nonalcoholic fatty liver disease, and…
Read More...

Opiant Pharmaceuticals, Inc. announced that it has signed an agreement with Sanofi to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute…
Read More...

REGENXBIO Inc. announced an expansion of its pipeline to include novel treatments for hereditary angioedema (HAE) and neurodegenerative diseases, including tauopathies, using NAV…
Read More...

Uman Diagnostics, now part of Quanterix, and Bio-Techne announced a strategic License and Supply Agreement for the antibodies used in the quantification of neurofilament light (Nf-L) on…
Read More...

Ligand Pharmaceuticals Incorporated announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash. Ab Initio was a…
Read More...

Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the US. Under the terms of the…
Read More...

Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of adult…
Read More...

Merck, known as MSD outside the United States and Canada, and Eisai announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for KEYTRUDA,…
Read More...

As part of the Company’s 10-year initiative to drive progress against tuberculosis (TB), Johnson & Johnson today announced that it has launched an international research consortium…
Read More...

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic…
Read More...

Avalon GloboCare Corp. announced that they have established a strategic partnership with GE Healthcare. The partnership will accelerate Avalon’s standardization, automation and…
Read More...

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, is pleased to report that the Company has executed a license agreement with Alfasigma S.p.A to develop and…
Read More...

Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection). Myxredlin (pronounced…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar…
Read More...

ACADIA Pharmaceuticals Inc. announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with…
Read More...

Vertex Pharmaceuticals Incorporated announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and…
Read More...

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral…
Read More...